September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
TRPV1 antagonist suppresses allergy response in allergic conjunctivitis Murine Model, rather than TRPA1 antagonist
Author Affiliations & Notes
  • Ji Young Kwon
    Catholic Institute of Visual Science, Seoul, Korea (the Republic of)
  • Hyun Soo Lee
    Catholic Institute of Visual Science, Seoul, Korea (the Republic of)
    Seoul St. Mary`s Hospital, Seoul, Korea (the Republic of)
  • Chang Rae Rho
    Daejeon St. Mary's Hospital, Daejeon, Korea (the Republic of)
  • HeeJung Ju
    Catholic Institute of Visual Science, Seoul, Korea (the Republic of)
  • Choun-Ki Joo
    Catholic Institute of Visual Science, Seoul, Korea (the Republic of)
    Seoul St. Mary`s Hospital, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Ji Young Kwon, None; Hyun Soo Lee, None; Chang Rae Rho, None; HeeJung Ju, None; Choun-Ki Joo, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 308. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Ji Young Kwon, Hyun Soo Lee, Chang Rae Rho, HeeJung Ju, Choun-Ki Joo; TRPV1 antagonist suppresses allergy response in allergic conjunctivitis Murine Model, rather than TRPA1 antagonist
      . Invest. Ophthalmol. Vis. Sci. 2016;57(12):308.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Recently studies performed on TRP(transient receptor potential, TRP) channel for thermal and mechanical stimulation demonstrate that it affects inflammatory immune responses as well as pain sensation. In this study, we investigated the immunological role of TRPA1 and TRPV1 in allergic conjunctivitis murine model.

Methods : 7-8 week-old BALB/c mice were sensitized via intraperitoneal injection once with Ovalbumin (OVA) and aluminum hydroxide. Mice were rested for 2 weeks and then challenged by instillation of OVA eyedrops once daily for 13 days. The expression of TRPA1 and TRPV1 was performed by western blot and immunohistochemistry in the allergic conjunctivitis model. Mice that OVA sensitized and by intraperitoneal injection once with aluminum hydroxide were rested for 2 weeks and then challenged by instillation of OVA eyedrops once daily for 13 days. HC-030031 (TRPA1 antagonist, HC) and Capsazepine (TRPV1 antagonist, Cap) eyedrops were administered 20min before OVA challenge once daily. Clinical signs were measured and we evaluated the infiltration of eosinophils and mast cells into conjunctiva with flow cytometry, and serum levels of OVA specific IgE production and Th2 cytokines in vitro stimulation of T cell in drainage lymph nodes (LN).

Results : In allergic conjunctivitis, TRPA1 expression was increased only in lymph node, but TRPV1 expression was increased in both conjunctiva and lymph node and TRPV1 was expressed mainly at T cell area. Cap treated mice showed less allergic conjunctivitis indicated by clinical signs and decreased production of serum OVA specific IgE. In addition, Cap treatment led to decreased infiltrations of CD45 positive immune cells, eosinophils and mast cells into conjunctiva, compare to only vehicle treated (control) mice. Cap administration suppressed Th2 cytokine production in vitro T cells assay.

Conclusions : Taken together, these results suggest that Capsazepine could suppress the Th2 response in drainage LNs and conjunctival eosinophil infiltration, as the therapeutic potential of topical Capsazepine for allergic conjunctivitis.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×